Virbac has established a local manufacturing partnership in China to meet the growing demand for veterinary products, enhancing its competitive position in the rapidly expanding pet care market.
Information on the Target
Virbac, a global leader in animal health, specializes in the development of a wide range of veterinary products for both companion animals and farm animals. Their portfolio includes innovative solutions for nutrition, dermatology, vaccines, and other health-related products. With a focus on ensuring animal welfare and preserving the human-animal bond, Virbac is committed to enhancing the quality of life for pets and livestock alike.
Recently, Virbac has made significant strides in the Chinese market by establishing a local manufacturing partnership. This strategic initiative is designed to meet the growing demand for veterinary products stemming from China’s expanding pet ownership and rising middle class. By localizing production, Virbac aims to increase the availability of essential health solutions tailored specifically for Chinese consumers.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The animal health industry in China is experiencing rapid growth, driven by a burgeoning middle class and an increasing number of pet ownership. The country's pet population is expanding at an unprecedented rate, leading to a correspondingly hig
Similar Deals
VivaVision → Jiangxi Shanliang Pharmaceutical Co., Ltd.
2024
Virbac
invested in
local manufacturing partnership
in 2025
in a Joint Venture deal